ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1068

Association Between Social Determinants of Health Domains and COVID-19-Related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data

Londyn Robinson1, jerrod anzalone2, Jasvinder Singh3, Kaleb Michaud2, Lesley Jackson4, Maria I. ("Maio") Danila5, Dongmei Li6, Rena Patel4 and Namrata Singh7, 1University of Washington, Seattle, WA, 2University of Nebraska Medical Center, Omaha, NE, 3Baylor College of Medicine, Houston, TX, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, 6University of Rochester School of Medicine and Dentistry, Rochester, NY, 7University of Washington, Bellevue, WA

Meeting: ACR Convergence 2025

Keywords: Access to care, COVID-19, Disparities, Health Services Research, socioeconomic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1055–1087) Healthcare Disparities in Rheumatology Posters

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Although studies have been published on the baseline characteristics of patients with autoimmune rheumatic diseases (AIRDs) with COVID-19 infection, little data exists on how social determinants of health (SDoH) influence outcomes. We investigated whether specific domains of SDoH are associated with COVID-19-related hospitalizations in adults with and without AIRDs.

Methods: We conducted a retrospective cohort study using electronic health record (EHR) data from the National Clinical Cohort Collaborative (N3C) COVID Enclave. We included adults ≥18 years who tested positive for SARS-CoV-2 (PCR or antigen test or diagnostic code) between April 2020 and March 2024. We identified patients with AIRD by the presence of ≥2 ICD-10 codes for an AIRD diagnosis, recorded ≥ 30 days apart before an incident COVID-19 infection. The AIRD diagnoses we included were polymyalgia rheumatica, polymyositis, dermatomyositis, rheumatoid arthritis, systemic sclerosis, ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis, reactive arthritis, Behcet’s disease, ANCA-vasculitis, giant cell arteritis, polyarteritis nodosa, SLE, and Sjogren’s syndrome. Only individuals with available SDoH data in N3C were included in this study and SDoH were assessed at the time of incident COVID-19 infection. SDoH were assessed across three Healthy People 2030 domains: healthcare access, economic stability, and social cohesion. The primary outcome was COVID-19-related hospitalization defined as occurring within a window from 3 days before to 14 days after diagnosis. To examine the association between specific SDoH domains and COVID-19-related hospitalization among adults with and without AIRDs, we conducted hierarchically nested logistic regression models and adjusted for covariates including age, sex, comorbidities, and vaccination status, then stratified analyses by AIRD status.

Results: There were 362,359 people with incident COVID-19 infection and available SDoH domains in N3C at the end of data collection, of whom 16,261 (4.5%) had at least one AIRD diagnosis. In unadjusted analyses, COVID-19-related hospitalization was significantly higher among AIRD patients (19%) compared to non-AIRD patients (13%, p < 0.001; Table 1). Across both AIRD and non-AIRD groups, having SDoH issues was associated with higher odds of COVID-19-related hospitalization (Table 2). In adjusted models including all SDoH domains, associations were consistently stronger among the AIRD group. Having access to healthcare issues was associated with higher hospitalization risk in both groups, with a larger effect in AIRD patients (aOR 1.73, 95% CI 1.41-2.11) than in non-AIRD patients (aOR 1.55, 95% CI 1.45-1.66). Similarly, social cohesion issues (aOR 1.44 vs 1.19) and economic instability (aOR 1.20 vs 1.16) had a more pronounced association with hospitalization in the AIRD group (Table 2).

Conclusion: Having SDoH issues was independently associated with higher odds of COVID-19-related hospitalization among adults, regardless of AIRD status. These associations were stronger in those with AIRDs, highlighting how underlying social disadvantage may exacerbate vulnerability to severe outcomes in this population.

Supporting image 1Table 1. Baseline characteristics of patients with and without AIRDs who had incident COVID-19 infection between April 2020 and March 2024.

Supporting image 2Table 2. Odds of COVID-19-related hospitalization among Social Determinates of Health (SDoH) domains, stratified by presence of AIRD. Adjusted covariates included age, sex, comorbidities, and COVID-19 vaccination status prior to incident infection.


Disclosures: L. Robinson: None; j. anzalone: None; J. Singh: American College of Rheumatology, 2, Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, 11, Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consu, 2, GeoVax Labs, Adaptimmune Therapeutics, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Aebona Pharma, 11, Intuitive Surgical Inc./Philips Electronics North America, 12, food and beverage payments, ROMTech, Atheneum, Clearview healthcare partners, Yale, Hulio, Horizon Pharmaceuticals/DINORA, ANI/Exeltis, USA Inc., Frictionless Solutions, Schipher, 2, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; the National Institutes of Health, 2, Zimmer Biomet Holdings, 5; K. Michaud: None; L. Jackson: None; M. Danila: Boehringer-Ingelheim, 2, Pfizer, 5; D. Li: None; R. Patel: None; N. Singh: None.

To cite this abstract in AMA style:

Robinson L, anzalone j, Singh J, Michaud K, Jackson L, Danila M, Li D, Patel R, Singh N. Association Between Social Determinants of Health Domains and COVID-19-Related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/association-between-social-determinants-of-health-domains-and-covid-19-related-hospitalization-in-individuals-with-autoimmune-rheumatic-diseases-a-retrospective-analysis-of-national-u-s-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-social-determinants-of-health-domains-and-covid-19-related-hospitalization-in-individuals-with-autoimmune-rheumatic-diseases-a-retrospective-analysis-of-national-u-s-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology